Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the Treatment of Subjects With Osteoarthritis Knee Pain

NCT00790790 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00790790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00790790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the Treatment of Subjects With Osteoarthritis Knee Pain
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2008
Completion date
January 31, 2010
Enrollment
147 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis knee pain